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minutes at teaching hospitals and 175 minutes at non-teaching hospitals. There 
were significant variations in duration of routine ED visits across race groups at 
teaching and non-teaching hospitals. The risk-adjusted results show that the 
mean duration of routine ED visits for black/African American and Asian 
patients when compared to visits for white patients was shorter by 10.0 and 3.4 
percent, respectively, at teaching hospitals; and longer by 3.6 and 13.8 percent, 
respectively, at non-teaching hospitals. Hispanic patients experienced 8.7 
percent longer ED stays when compared to white patients at non-teaching 
hospitals. CONCLUSIONS: There is significant racial disparity in the duration of 
routine ED visits, especially in non-teaching hospitals where non-white patients 
experience longer ED stays compared to white patients. The variation in duration 
of routine ED visits at teaching hospitals when compared to non-teaching 
hospitals was smaller across race groups.  
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DRG SYSTEM IN ITALY: EVALUATION OF DIFFERENT REIMBURSEMENTS  
FOR SURGICAL PROCEDURES AT NATIONAL, REGIONAL AND HOSPITAL  
LEVEL  
Velleca M1, Petrarca G2, Perrone F1 
1Johnson & Johnson Medical, Pomezia (RM), Italy, 2Centro Studi Assobiomedica, Milano, Italy  
OBJECTIVES: The Italian National Health Service (Servizio Sanitario Nazionale-SSN) 
is structured on two levels: the national and regional level. The national 
government defines the benefits package (essential levels of care, livelli essenziali 
di assistenza-LEA) to which citizens are constitutionally entitled and which each 
Regional Health Service (Servizio Sanitario Regionale-SSR) is responsible for. Since 
1997 the regions have been fully autonomous in organizing and managing their 
SSR, including the definition of DRG tariffs for hospital admissions. The aim of 
this study is compare the regional differences among tariffs for the main surgical 
DRGs of each Major Diagnostic Category (MDC). METHODS: In order to identify 
the surgical DRGs with the highest volumes for each MDC, we used the dataset 
of admissions registered in 2010 by all hospitals (DRG version 24 ICD9-CM), 
published by the Italian Department of Health (Ministero della Salute), and we 
analyzed the variability among tariffs by calculating their average and standard 
deviations (the extra-reimbursement has not been considered). RESULTS: 
Average tariffs were calculated starting from the standard regional tariff for each 
DRG. Comparing the first 10 DRGs, we identified a variation in the average tariff 
which rose from -1.8% to +22.6% and a standard deviation with a minimum of 
425€ and a maximum of 1443€. Further complexity is given by the intra-regional 
variation by type of hospital, where we observed a variation inside the same 
region of 82% for the same DRG. CONCLUSIONS: The SSN is characterized by a 
high variability of regional DRG tariffs, also inside the regions. Moreover in Italy 
there is not a defined procedure to update the classification of DRGs and the 
related tariffs. Therefore there is a need to establish a systematic periodical 
review, which should involve all the different stakeholders of SSN, and to share 
data updated with them about the volume of admissions.  
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SWITCHING THE PERFORMANCE VOLUME LIMIT (PVL) TO DEGRESSIVE 
FINANCING METHOD IN THE HUNGARIAN DRG-BASED HOSPITAL 
REIMBURSEMENT BETWEEN 2009-2012  
Endrei D, Decsi T, Bódis J, Zemplényi A, Ágoston I, Molics B, Boncz I 
University of Pécs, Pécs, Hungary  
OBJECTIVES: The aim of our study was to investigate the financial effects of 
switching from the so-called performance volume limit (PVL) to degressive 
financing method in the Hungarian DRG-based hospital financing. METHODS: 
The data in our analysis were derived from the nationwide administrative 
dataset of the National Health Insurance Fund Administration (OEP), the only 
health care financing agency. We examined mainly the period between 2009 and 
2012. The difference in hospital reimbursement between the preannounced DRG 
reimbursement rate and degressive cap (upper ceiling) was calculated both on 
national level and in the case of the Clinical Center of the University of Pécs. 
RESULTS: The ratio of partially paid [based on preannounced performance base-
fee (PPBF) or performance volume limit (PVL) financing method] active inpatient 
cost-weights to total cost-weights varied extremely between 2009-2012. In the 
case of PPBF financing in 2009, 25-30% of the total national performance fell 
under floating fee structure, resulting in a monthly change in the monetary 
(Hungarian Forint, HUF) value of a DRG cost-weight. In the case of degressive PVL 
from 2011 onwards, one to seven percent of the national performance fell in the 
degressive zone, with a prefixed value of HUF 45,000/cost-weighs. For the Clinical 
Centre of the University of Pécs, this partial reimbursement resulted in a large 
financial deficit in 2009, when PPBF was applied. In 2010 and 2011, the deficit of 
the University of Pécs lessened to some extent compared to 2009; however, it 
was still rather high (HUF 1.46 and HUF 1.3 billion, respectively). Due to partial 
health insurance reimbursement, the University of Pécs realized HUF 8.1 billion 
revenue losses between 2004 and 2012. CONCLUSIONS: Application of 
preannounced performance base-fee rendered institutional financing nearly 
incalculable. Renewed introduction of degressive performance volume limit in 
2011 made institutional financing more calculable; however, it failed to entirely 
stop source withdrawal.  
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TRENDS IN USE OF HEALTH ECONOMIC EVIDENCE FOR DEVELOPING CLINICAL 
GUIDELINES  
Aggarwal S, Topaloglu H, Kumar S, Segal J, McGrane M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: The recent reforms and policy changes have increased the cost 
pressures on all health care stakeholders, including clinical experts. In the past, 
clinical guidelines were developed independent of cost or economic 
considerations. However, increasingly, more clinical guidelines are mentioning 
cost concerns and referring to economic data in new recommendations. The 
objective of this study was to analyze trends in the use of health economic 
information for developing clinical guidelines. METHODS: To understand trends 
in use of health economic information we conducted targeted search for clinical 
guidelines, expert recommendations, and consensus statements with specific 
mention of “cost” or “economic” or related terms. A systematic literature search 
was undertaken for the databases Pubmed, Google Scholar and Cochrane. The 
guidelines published between 2003-2012 were included. For guidelines which 
met the search criteria, data was collected for the name of the authors, 
indication, year of publication, country/region, and context of use of 
cost/economic evidence. RESULTS: Sixteen clinical guidelines published between 
2003-2012 met the inclusion criteria for specific mention of cost/economic 
evidence. More than 50% of these guidelines were published between 2006-2012. 
For indication, 3 out of 16 guidelines were for diabetes, while the rest were for 
different indications. In these16 guidelines “cost effectiveness” was mentioned 
14 times, either referencing cost-effectiveness data or to mention the importance 
of such data for selecting treatment options. The guidelines commonly cite high 
cost of disease or high economic burden as one of the considerations for 
developing new recommendations (11 out of 16). Another term that was 
commonly used by these guidelines was “cost-benefit,” which was mentioned 5 
times in these guidelines. Notably, QALY was rarely mentioned (1 out of 16 
times) in these guidelines. CONCLUSIONS: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and 
incorporate health economic information for developing new recommendations.  
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ANALYSIS OF THE WAXMAN-HATCH ACT PHARMACEUTICAL PATENT 
EXTENSIONS (1984-2012)  
Bin Sawad AH1, Alshahrani AM1, Seoane-Vazquez E2, Rodriguez-Monguio R3 
1Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA, 2MCPHS 
University, Boston, MA, USA, 3University of Massachusetts, Amherst, MA, USA  
OBJECTIVES: The Drug Price Competition and Patent Term Restoration Act of 
1984 (Waxman- Waxman Act - WHA) established a patent extension system that 
allows sponsors of new drugs (NDAs) and biologic applications (BLAs) approved 
by Food and Drug Administration (FDA) to recover part of the patent time 
dedicated to clinical trials and to the FDA drug review process. The maximum 
extension is 5 years and the effective patent life from approval to patent 
expiration cannot exceed 14 years. We assessed the characteristic of drugs and 
biologics that had a patent extension in the period 1984-2012 and examined the 
patent life timeline from clinical trials to regulatory review, and from marketing 
authorization to patent expiration (i.e. effective patent life). METHODS: Data 
were derived from the FDA, the US Patent and Trademark Office, and the US 
Federal Register. Descriptive analyses were performed. T-test was used to assess 
differences in averages. Significant level was set at 0.05. RESULTS: The USPTO 
listed 499 pharmaceuticals with patent extensions in the study period; 453 NDAs 
(90.8%), 38 BLAs (7.6%), and 9 vaccines (1.8%). Drug regulatory and patent 
information was available for 323 pharmaceuticals (287 NDA, 32 BLA and 4 
vaccines). The average±stdev patent extension was 2.7±1.4 years (median=2.2 
years; 95% CI=2.62.8). The extension was longer for vaccines (3.7±1.3 years) than 
for NDAs (2.7±1.4 years) and BLAs (2.4±1.5 years). The average clinical trials time 
was 5.9±3.1 years, being similar for NDAs, BLAs and vaccines. The average FDA 
review time was 1.7±1.3 years (higher for vaccines 2.6±2.5 years). The average 
length of the effective patent life was 8.7±7.0 years without patent extensions 
and 11.7±6.8 years after the extensions. CONCLUSIONS: A large number of 
pharmaceuticals were granted patent extensions in the US. The WHA 
significantly increased the effective patent life of pharmaceuticals.  
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PRELIMINARY STUDY ON DEVELOPMENT OF BUDGET IMPACT ANALYSIS 
GUIDELINES IN KOREA: THE COMPARISON OF GUIDELINES ON BUDGET IMPACT 
ANALYSIS FOR HEALTH TECHNOLOGIES  
Jeon HR, Lim MK, Yu SY 
Health Insurance Review & Assessment Service, Seoul, South Korea  
OBJECTIVES: A budget impact analysis(BIA) is a useful tool for a health care 
decision maker in estimating the financial impact of the new technology. In 
Korea, the content and presentation of results of the BIA have been proposed but 
detailed guidance on methods for BIA are not yet available. To evaluate the 
international landscape of BIA guidance, we compared guidelines of BIA outside 
of Korea. METHODS: A literature review was performed. Research for guidelines 
was based on data published in latest official papers or reports from ISPOR and 
national institutes in Canada, Ireland, and Poland. RESULTS: In all guidelines, 
the recommended perspective was that of public purchaser. A time horizon of 2-
5 years was considered to be desirable. It was stated that data on a technology 
and its use should be included in BIA, which is helpful for decision makers. 
Published guidelines provided a similar description of target population, but it 
was different whether or not off-label usage of drugs was included in 
assumption of population size. The approaches to measurement and evaluation 
of costs varied in different regions. The costing included direct costs associated 
with the technology in four guidelines but items of other costs were specified 
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differently. When analysts report the results of study, both total and incremental 
budget impact should be presented for each year of the time horizon. Sensitivity 
analysis was emphasized in order to identify the uncertainty within the analytic 
framework. The guidelines suggested that the discounting is unnecessary and 
encourage model validation except those of Poland. CONCLUSIONS: This review 
discovered that Canada, Ireland, Poland, and ISPOR BIA guidelines were 
consistent in basic analytic framework, but details were depended on payer 
perspective and regional specificity. This study is expected to help to develop 
Korean BIA guidelines.  
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A COMPARISON OF NEW DRUGS APPROVED BY THE EMA AND THE FDA IN 
2006-2011  
Alshehri N1, Seoane-Vazquez E2, Rodriguez-Monguio R3 
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2MCPHS University, 
Boston, MA, USA, 3University of Massachusetts, Amherst, MA, USA  
OBJECTIVES: The European Medicines Agency (EMA) and the United States Food 
and Drug Administration (FDA) have different regulatory systems for the review 
and approval of new drugs. This study reviewed and compared the 
characteristics of priority review new pharmaceuticals (i.e. new molecular 
entities -NME- and new therapeutic biologics -BLA-) approved by EMA and the 
FDA in the period 2006-2011. METHODS: Data were extracted from the FDA and 
EMA websites. Dates of application and approval and orphan status information 
were extracted from the FDA approval letters and the EMA public assessment 
reports. Descriptive statistics were used to compare the approval processes and 
characteristics of both systems; t-test was used to assess differences in average 
review time. Significant level was set at 0.05. RESULTS: A total of 47 drugs (34 
NME and 13 BLA) were approved by both regulatory agencies in the study period. 
BLAs were submitted to the FDA 22±166 days earlier (median=10 days) and 
approved by the FDA 211±145 days earlier (median=168 days) than the EMEA. 
NMEs were submitted to the EMA 229±832 days earlier (median=33) and 
approved by the EMA 97±884 days earlier (median=173 days) than the FDA. The 
average review time was statistically significantly lower (p<0.001) for the FDA 
258±200 days (median=184 days) than for EMA 406±96 (median=407 days). The 
number of products with orphan designation at the time of the first approval 
was higher in the FDA (n=20) than in the EMA (n=15). EMA granted orphan 
designation at the time of approval to two products that did not have orphan 
designation in the US. CONCLUSIONS: There are significant differences in the 
time elapsed between the filing and the approval of priority review products in 
the US and EU. Orphan designation also varied between the two regulatory 
systems. Harmonization of the regulatory systems could facilitate timely 
approval of essential pharmaceuticals.  
 
PHP13  
AN EVALUATION OF THE ASSOCIATION BETWEEN AN FDA SUICIDALITY 
WARNING AND ANTIEPILEPTIC MEDICATION USE IN A STATE MEDICAID 
PROGRAM  
Mittal M1, Harrison DL1, Thompson DM1, Miller MJ2, Farmer KC1, Ng YT1 
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2University of 
Oklahoma Health Sciences Center, Tulsa, OK, USA  
OBJECTIVES: In January 2008, the Food and Drug Administration (FDA) 
communicated concerns and later in May 2009, issued a warning about an 
increased risk of suicidality related to all antiepileptic drugs (AEDs). The purpose 
of this study is to evaluate the association between an FDA suicidality warning 
and AED use among Oklahoma Medicaid enrollees diagnosed with epilepsy 
and/or psychiatric disorder(s). METHODS: A longitudinal interrupted design was 
conducted to study Oklahoma Medicaid claims data from January 2006 through 
December 2009. A total of 13,126 individuals met the study criteria: diagnosis 
with epilepsy and/or psychiatric disorder(s) and filling of at least one AED 
prescription. A segmented logistic regression model compared the level and 
trend in the log odds of AED use among three time periods: a baseline period of 
25 months (Jan. 2006 - Jan. 2008) before the FDA warning; the 16 months (Feb. 
2008-May 2009) during the FDA warning; and the 7 months (June 2009-Dec. 2009) 
after the FDA warning. Generalized estimation equations (GEE) were used to 
estimate trends in AED utilization while adjusting for several covariates. 
RESULTS: There was a statistical increase in the trend, expressed as a monthly 
change in log odds of AED use, before the FDA warning period (p<0.0001). 
However, this trend decreased by 34% (99% CI: 10.2% to 57.6%, p=0.0002) during 
the FDA warning period when compared to the baseline trend. This decrease in 
trend did not remain significant after the FDA warning period (p=0.2957). 
Compared with the baseline level of AED utilization before the FDA warning 
period, the log odds of AED utilization level also decreased by 22% (99% CI: 1.9% 
42.2%, p=0.0048) after the FDA warning period. CONCLUSIONS: The FDA 
suicidality warning was associated with a reduction in overall AED use among 
this population.  
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THE IMPACT OF KOREAN PROSPECTIVE DRUG UTILIZATION REVIEW PROGRAM 
ON THE RATE OF DRUG-DRUG INTERACTIONS  
Kim DS, Jeon HR, Kang HA, Park CM 
Health Insurance Review & Assessment Service, Seoul, South Korea  
OBJECTIVES: Since December 2010, online computerized prospective DUR(pDUR) 
has been implemented in Korea. pDUR involves the review of each prescription 
before the medication is dispensed to the individual patient. The pDUR is 
performed electronically by Health Insurance Review & Assessment Service 
(HIRA), which is a Korean governmental agency, and then HIRA provides medical 
institutions and pharmacies with information that can be helpful to them in 
preventing potential drug problems such as drug/drug interactions or ingredient 
duplication. The aim of this study was to assess the impact of the Korean pDUR 
implementation on the rate of drug-drug interactions (DDIs) using claims data of 
HIRA. METHODS: A before-after comparison of the prevalence of DDIs was 
conducted, using HIRA administrative claims data from medical institutions 
from January 2010 to December 2011. In addition, a paired t-test was applied to 
examine the difference between the pre- and post-pDUR. The analysis unit was 
the prescription issued and main outcome measures were the rates of DDIs 
within- (control group) or between- physician encounters. RESULTS: The mean 
DDIs rates (pre-test and post-test) within patient visits were 0.29‰ and 0.22‰, 
respectively. The mean rates of DDIs between visits were 0.94‰ (before) and 
0.80‰ (after). As a result of the t-test, we found that DDIs rate between 
encounters decreased significantly (t=3.04, p=0.0026) after the implementation of 
pDUR, whereas there is no significant reduction within encounters (t=1.15, 
p=0.2518). With respect to the prevalence of DDIs between drug groups, the most 
dramatic reduction was occurred between HMG CoA reductase inhibitors and 
anti-fungal agents. CONCLUSIONS: It seems effective that giving a direct 
feedback to prescribers by a prospective DUR. Further research is needed to 
assess the impact of DUR to final outcomes such as hospitalization.  
 
PHP15  
“SAFE AND EFFECTIVE” VERSUS “REASONABLE AND NECESSARY”: IS THE 
DECK STACKED AGAINST DEVICES?  
Mordin M1, Hogue S2, Barrows S1, Van Amerongen D3 
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI-Health Solutions, Research Triangle Park, NC, 
USA, 3Humana, Cincinnati, OH, USA  
OBJECTIVES: US Food and Drug Administration (FDA) approval does not 
necessarily equate with coverage by the Centers for Medicare and Medicaid 
Services (CMS) or private payers for a device or a drug. The FDA is charged with 
determining the safety and efficacy of medical products. In contrast, payers are 
primarily concerned with whether medical products are reasonable and 
necessary. As health care costs continue to rise, manufacturers face increasing 
pressures to justify product prices and provide rationale to payers to support 
favorable funding decisions. Our objective was to review coverage decisions for 
devices and reasons for noncoverage to determine whether payers are expecting 
more pharmaceutical-like evidence. METHODS: We reviewed Washington State 
Health Technology Assessment (HTA) decisions for therapeutics from 2007 
through 2012. Reasons for noncoverage were classified as lack of clinical efficacy 
or other. RESULTS: We identified 22 therapeutic HTA reviews, of which 11 
included some level of noncoverage determination for the product or procedure. 
The reason for noncoverage was stated as a perceived lack of clinical efficacy 
evidence. For example, a 2008 decision against implantable infusion pumps for 
the treatment of chronic noncancer pain was based partly on the fact that “[t]he 
only kind of evidence about whether implantable infusion pumps are effective 
for patients with chronic noncancer pain comes from uncontrolled case series.” 
Such statements demonstrate the disparity between FDA approval of devices 
and payer expectations for efficacy evidence to support coverage decisions. 
Payer evidence requirements for medical devices continue to move closer to 
those historically associated with pharmaceuticals. CONCLUSIONS: No roadmap 
exists for determination of reasonable and necessary levels of evidence for 
device-coverage decisions. FDA and payer evidence requirements are not 
aligned. Moving forward, evidence-generation efforts for devices will, in most 
cases, have to exceed FDA requirements in order for payer evidence needs to be 
met.  
 
PHP16  
REVIEWING AND REFINING THE CONCEPTUAL FRAMEWORK FOR THE 
CURRENT DRUG DEVELOPMENT PARADIGM (CDDP)  
Rosenberg E1, Pistollato M2, Deverka PA1, Mestre-Ferrandiz J2 
1Center for Medical Technology Policy, Baltimore, MD, USA, 2Office of Health Economics, London, 
UK  
OBJECTIVES: To examine how five global pharmaceutical companies are 
currently developing comparative effectiveness research (CER) and relative 
effectiveness (RE) evidence. METHODS: We followed two parallel steps. First, a 
targeted literature review was performed. Second, a semi-structured interview 
program was conducted with 19 senior key informants (KI) across the five 
companies. After analyzing the interview results using systematic content 
review, we merged these findings with the literature review to extrapolate the 
final study results. RESULTS: We found a clear recognition of the growing 
importance of CER/RE within the industry, although the KIs differed regarding 
whether this was a disruptive change or simply an extension of traditional 
outcomes research efforts. Most viewed the payer/HTA community as the 
biggest driver of CER/RE evidence needs, rather than patients or clinicians. 
Nearly all KIs stated that their organizations already incorporate CER/RE criteria 
into their current drug development paradigm (CDDP), but differed in the timing 
(phase of development), degree of investment, whether CER/RE considerations 
influenced go/no-go decisions and type of product. Barriers to adaptation of the 
CDDP included historic prioritization of regulatory approval; concerns about 
increased study costs and complexity; heterogeneity of stakeholder evidence 
requirements; and difficulty integrating across departments. Facilitators of 
change included increasing CER/RE expectations of payers/HTA bodies and 
having senior management serve as an internal CER/RE champion. Most 
interviewees believed that CER/RE would play a greater role in drug development 
by 2020, particularly driven by payer/HTA demands for evidence of value. 
CONCLUSIONS: Our interviews revealed that there has been a spectrum  
of response to the perceived need for CER/RE data that involves altering the 
CDDP in a variety of important ways to include primarily the information needs 
of payers and HTA bodies. These changes to the CDDP are projected to grow  
